Trial Profile
Apatinib Versus Bevacizumab in Combination With Second-line FOLFIRI in Patients With Metastatic Colorectal Cancer That Progressed During or After First-line Bevacizumab Plus an Oxaliplatin-based Regimen: A Randomised Phase 2 Trial
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 05 Jan 2023
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary) ; Bevacizumab; Fluorouracil; Folinic acid; Irinotecan
- Indications Adenocarcinoma; Colorectal cancer
- Focus Therapeutic Use
- Acronyms ABST-C
- 20 Jan 2019 Status changed from not yet recruiting to recruiting.
- 08 Sep 2017 New trial record